| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.055 | 0.8 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.027 | 0.8 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |